Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
Portfolio Pulse from
Biodexa Pharmaceuticals has appointed Precision for Medicine as the CRO for the European component of its Phase 3 study of eRapa in Familial Adenomatous Polyposis (FAP). The U.S. component will be managed by LumaBridge.
March 06, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biodexa Pharmaceuticals has appointed Precision for Medicine as the CRO for the European component of its Phase 3 study of eRapa in FAP, indicating progress in its clinical trials.
The appointment of a CRO for the European component of a Phase 3 study is a significant step in advancing Biodexa's clinical trials. This progress is likely to be viewed positively by investors, potentially boosting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100